Hummingbird Bioscience Doses First Patient in Phase I Trial of HER3-Targeted ADC HMBD-501
核心洞察
Hummingbird Bioscience (搜索) has dosed the first patient in a Phase I clinical trial of HMBD-501, a next-generation HER3 (搜索)-targeted antibody-drug conjugate for advanced HER3-expressing solid malignancies (搜索).
HMBD-501 features an exatecan payload and has been engineered using proprietary technologies to potentially deliver enhanced efficacy and safety compared to previous generation ADCs.
The Phase I dose escalation trial is being conducted at multiple U.S. sites, with initial data expected in the second half of 2026.
Hummingbird Bioscience (搜索) announced the dosing of the first patient in a Phase I clinical trial evaluating HMBD-501, a next-generation HER3 (搜索)-targeted antibody-drug conjugate (ADC) for patients with advanced HER3-expressing solid malignancies (搜索). The trial (NCT06956690) represents a significant milestone for the Singapore-based biotherapeutics company's oncology pipeline.
Novel HER3-Targeted ADC Design
HMBD-501 is engineered with an exatecan payload and has been optimized for safety and efficacy through Hummingbird Bioscience (搜索)'s proprietary antibody discovery and engineering platform combined with state-of-the-art ADC technologies. The company positions the therapeutic as a potentially best-in-class HER3 (搜索)-targeted ADC with a differentiated mechanism of action.
According to the company, multiple HER3 (搜索)-positive tumor settings have demonstrated response to HER3-ADC therapeutic approaches, providing rationale for targeting this pathway in solid malignancies.
Clinical Development Progress
The Phase I dose escalation trial is currently underway at multiple sites across the United States. Initial data from the dose escalation portion of the study is expected in the second half of 2026, which will guide subsequent development phases.
"Dosing the first patient in this trial is a significant milestone for the HMBD-501 program and reflects years of research and development on HER3 (搜索) by the Hummingbird Bio team," said Jerome Boyd-Kirkup, PhD, Chief Scientific Officer at Hummingbird Bioscience (搜索). "We now look forward to generating high-quality clinical data that will guide the next phases of development."
Therapeutic Differentiation Strategy
Hummingbird Bioscience (搜索) has developed HMBD-501 to potentially deliver enhanced efficacy and safety profiles compared to previous generation ADCs through key proprietary technologies. The company's approach combines computational and systems biology technologies with traditional drug discovery methods.
Kevin N. Heller, MD, Chief Medical Officer at Hummingbird Bioscience (搜索), emphasized the clinical significance of this development milestone: "First-patient dosing marks a meaningful step forward as we begin evaluating our investigational therapy in cancer (搜索) patients. This is an important step in translating our science into a potential new therapy to treat cancer."
Company Pipeline and Platform
Hummingbird Bioscience (搜索) operates at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. The company's computational and systems biology technologies have generated a pipeline of clinical-stage monoclonal antibodies and antibody-drug conjugates targeting oncology and autoimmunity indications.